Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
List view / Grid view
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
Imaging Mass Cytometry™ of malignant tissue architecture: rare single cells to structured multi-cellular communities
14 April 2021 | By Fluidigm
Join us for our free live webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.